Background Procollagen C‐proteinase enhancer‐1 (PCPE‐1) is a 55 kDa glycoprotein, which increases the activity of procollagen C‐proteinases that break down C‐terminal propeptides. Studies have shown that PCPE‐1 is involved in the fibrotic process that occurs in various tissues and organs. Our review of the literature revealed no data concerning the relation between PCPE‐1 and chronic kidney disease (CKD). The purpose of this study was to determine PCPE‐1 levels in CKD. Methods One hundred thirty‐one CKD patients and 34 healthy controls were included in our study. Demographic data were recorded, and routine biochemical tests were performed. Blood specimens were collected for PCPE‐1 investigation. Demographic data, biochemical test results and PCPE‐1 levels were compared between the control and patient groups. Parameters affecting PCPE‐1 levels in our patient group were assessed. Results Procollagen C‐proteinase enhancer‐1 levels were significantly higher in our patient group compared to the control group. Parameters affecting PCPE‐1 elevation in the patient group were identified as systolic blood pressure, blood urea nitrogen, phosphorus, haemoglobin, intact parathormone levels, glomerular filtration rate and body mass index. Conclusion We determined high PCPE‐1 levels in CKD patients. PCPE‐1 levels being negatively correlated with glomerular filtration rate suggests that PCPE‐1 may be associated with progression in CKD patients.

No abstract

In the presence of periodontal diseases in UC and CD, altered cytokine responses may be observed.

Background/aim: Immune thrombocytopenia (ITP) is treated by corticosteroids and/or intravenous immune globulin as the first line treatment when necessary. Mean platelet volume (MPV) is a marker of platelet production and function. In this study, we aimed to search the relationship between the MPV and the treatment response in ITP patients and it was hypothesized that MPV can be used as a predictor of the response. Materials and methods:The 70 newly diagnosed adult primary ITP patients and 70 of healthy people were included. MPV between ITP and healthy population, MPV in the diagnosis and after the treatment between the responders and the nonresponders were compared. Results:The responders had significantly higher MPV and the nonresponders had significantly lower MPV than the healthy population (11.09 and 10.21 fL, P = 0.03; 9.38 and 10.21 fL, P = 0.001). MPV in the diagnosis was significantly higher in the responders than the nonresponders (11.09 and 9.38 fL, P = 0.005). MPV significantly changed after the treatment in the responders (11.09 to 9.32 fL, P = 0.004). Conclusion:MPV can be used as a predictor of early response to the first line treatment in newly diagnosed adult primary ITP patients.

In our study, sEPCR was high in hypertensive individuals, and this elevation was related to ARV and urine Na excretion independently of mean blood pressure.